May Health, formerly AblaCare, is developing a modern approach to PCOS.
Total raised: $36.7M
Funding Rounds 2
| Date | Series | Amount | Investors |
| 11.03.2026 | - | $11.7M | Trill Impa... |
| 13.05.2024 | Series B | $25M | Trill Impa... |
Mentions in press and media 9
| Date | Title | Description |
| 13.03.2026 | May Health Secures $11.7M for PCOS Infertility Breakthrough | May Health, a medical device innovator, closed an $11.7 million funding round. New investor Nexpring Health led the investment. Existing partners Sofinnova Partners, Bpifrance, and Trill Impact also participated. This capital fuels the REBA... |
| 11.03.2026 | May Health Raises $11.7M in Funding | May Health, a Menlo Park, CA-based developer of medical devices for polycystic ovary syndrome (PCOS), raised $11.7M in funding. The round was led by new investor Nexpring Health, with participation from existing shareholders Sofinnova Partn... |
| 10.03.2026 | May Health: $11.7 Million Raised To Advance PCOS-Related Infertility Treatment Technology | May Health, a medical device company focused on expanding treatment options for women living with polycystic ovary syndrome (PCOS), announced that it has raised €10 million (about $11.7 million) in new funding. The round included participat... |
| 14.05.2024 | May Health Secures $25M to Revolutionize PCOS Treatment | May Health, a Paris-based medical device company, recently closed a $25M Series B funding round led by Bpifrance and Trill Impact Ventures. The funding will propel the development of their innovative Ovarian Rebalancing™ therapy, aimed at a... |
| 13.05.2024 | May Health grabs $25m Series B | - |
| 13.05.2024 | Trill Impact Ventures co-leads USD 25 million series B financing round in May Health | Trill Impact Ventures co-leads USD 25 million series B financing round in May Health Mon, May 13, 2024 14:00 CET Report this content Advancing novel treatment for women suffering from Polycystic Ovary Syndrome related infertility. Trill Imp... |
| 13.05.2024 | May Health Raises $25M in Series B Funding | May Health, a Paris, France-based clinical-stage medical device company, raised $25M in Series B funding. The round was led by Bpifrance and Trill Impact with participation from founding investor Sofinnova Partners, as well as Avestria Vent... |
| 13.05.2024 | May Health raises $25M to address PCOS-related infertility | The company has developed Ovarian Rebalancing, a one-time, in-office procedure to induce ovulation Polycystic ovary syndrome (PCOS) is a lifelong endocrine disorder that affects 10% of women around the world, and can cause excess body hair,... |
| - | May Health | “May Health is developing a modern treatment - Ovarian Rebalancing - designed to restore ovulation for people with polycystic ovary syndrome.” |